2025 Asia-Pacific 23-Valent Pneumococcal Vaccine Market Revenue Opportunities Report
Description
The 2025 Asia-Pacific 23-Valent Pneumococcal Vaccine Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the 23-valent Pneumococcal Vaccine Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the 23-valent pneumococcal vaccine market in the Asia-Pacific region are Merck & Co., Pfizer, GlaxoSmithKline (GSK), and Sanofi. Merck & Co. leads with its Pneumovax 23 vaccine, leveraging its global distribution and vaccine development expertise. Pfizer offers Pneumovax 23 and Prevnar 13, with recent expansions such as their 20-valent conjugate vaccine gaining regulatory approval, enhancing their foothold in Asia-Pacific. GSK and Sanofi maintain competitive positions with their own PPSV23 vaccines, strong production capabilities, and extensive vaccine research pipelines. These companies invest heavily in expanding regional manufacturing and distribution networks amid rising pneumococcal disease prevalence and vaccination initiatives in Asia-Pacific.
Local firms like Walvax Biotechnology in China and the Serum Institute of India also contribute significantly, especially by developing vaccines targeting region-specific serotypes. The Asia-Pacific market growth is fueled by government vaccination programs, increasing healthcare infrastructure, and the expansion of private and public vaccination sectors. Strategic partnerships and new product launches remain critical for these companies to address challenges such as antibiotic resistance and vaccine accessibility in rural areas. Continuous investments in R&D and manufacturing capacity underpin their sustained presence and market leadership in the Asia-Pacific 23-valent pneumococcal vaccine landscape.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the 23-valent Pneumococcal Vaccine Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the 23-valent pneumococcal vaccine market in the Asia-Pacific region are Merck & Co., Pfizer, GlaxoSmithKline (GSK), and Sanofi. Merck & Co. leads with its Pneumovax 23 vaccine, leveraging its global distribution and vaccine development expertise. Pfizer offers Pneumovax 23 and Prevnar 13, with recent expansions such as their 20-valent conjugate vaccine gaining regulatory approval, enhancing their foothold in Asia-Pacific. GSK and Sanofi maintain competitive positions with their own PPSV23 vaccines, strong production capabilities, and extensive vaccine research pipelines. These companies invest heavily in expanding regional manufacturing and distribution networks amid rising pneumococcal disease prevalence and vaccination initiatives in Asia-Pacific.
Local firms like Walvax Biotechnology in China and the Serum Institute of India also contribute significantly, especially by developing vaccines targeting region-specific serotypes. The Asia-Pacific market growth is fueled by government vaccination programs, increasing healthcare infrastructure, and the expansion of private and public vaccination sectors. Strategic partnerships and new product launches remain critical for these companies to address challenges such as antibiotic resistance and vaccine accessibility in rural areas. Continuous investments in R&D and manufacturing capacity underpin their sustained presence and market leadership in the Asia-Pacific 23-valent pneumococcal vaccine landscape.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
